Trulicity ® (dulaglutide)

This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information.For current prescribing information for all Lilly products, including Summaries of Product Characteristics, Patient Information Leaflets and Instructions for Use, please visit: (England, Scotland, Wales) or (Northern Ireland).

Is there a Risk of Pancreatitis with Trulicity® (dulaglutide)?

Acute pancreatitis has been reported in association with dulaglutide In clinical trials. The use of GLP‑1 receptor agonists have been associated with a risk of developing acute pancreatitis.


How many cases of pancreatitis were reported in the dulaglutide clinical program?

The pancreatic safety of dulaglutide was assessed in an integrated analysis of 4 phase 2 and 5 phase 3 studies in 6005 patients with Type 2 Diabetes (T2D).1 

A blinded external adjudication committee evaluated and assessed the

  • investigator-reported adverse events (AEs) of pancreatitis
  • asymptomatic, confirmed increases in at least 1 pancreatic enzyme of ≥ 3 times the upper limit normal (ULN), and
  • AEs of severe or serious abdominal pain without a known etiology.1

The incidence of acute pancreatitis was

  • 0.07 % for dulaglutide compared to
  • 0.14 % for placebo. 

Acute pancreatitis and pancreatitis have also been reported in the post-marketing setting.2

In the integrated analysis, a total of 203 events were adjudicated in 151 patients. Pancreatitis was confirmed in 9 patients, of which 

  • 5 patients were treated with dulaglutide
  • 3 patients were treated with sitagliptin, and
  • 1 patient was receiving placebo.1

All 5 patients with confirmed pancreatitis who were being treated with dulaglutide had elevated pancreatic enzymes at baseline prior to initiation of dulaglutide.1

Acute Pancreatitis

Of the 9 patients with adjudicated pancreatitis, 7 patients had acute pancreatitis including

  • 3 patients treated with dulaglutide
  • 3 patients treated with sitagliptin, and
  • 1 patient receiving placebo.1

The type of pancreatitis was not determined in 1 of the 3 patients receiving dulaglutide. For data analysis, this case was categorized as “acute.” In the assessment of risk factors for acute pancreatitis, this patient had cholelithiasis.1

The exposure-adjusted incidence rates of acute pancreatitis were

  • 0.85 patients/1000 patient-years in the dulaglutide group
  • 4.71 patients/1000 patient-years in the sitagliptin group, and
  • 3.52 patients/1000 patient-years in the placebo group.1

Chronic Pancreatitis

There were 2 reported events of chronic pancreatitis in patients receiving dulaglutide.

The exposure-adjusted incidence rate of chronic pancreatitis was 0.57 patients/1000 patient-years in the dulaglutide group.1

Pancreatitis in the REWIND Study

The REWIND study was an event-driven, randomized, double-blind, phase 3 study evaluating once-weekly dulaglutide 1.5 mg treatment compared with placebo when added to standard of care on a composite endpoint of major adverse cardiovascular events (death due to cardiovascular causes, nonfatal myocardial infarction or nonfatal stroke) (MACE-3) in adults with T2D and established cardiovascular disease and/or risk factors.3,4

The instance of pancreatitis, did not differ significantly between the dulaglutide and placebo treatment groups (Acute Pancreatitis in the Dulaglutide REWIND Study).4

Acute Pancreatitis in the Dulaglutide REWIND Study4




P Value

Acute pancreatitisa




Imaging and enzymesb




Imaging, enzymes, and symptomsc




Abbreviation: REWIND = Researching cardiovascular Events with a Weekly INcretin in Diabetes.

aBased on the first occurrence of acute pancreatitis diagnosed on the basis of at least 2 of 3 diagnostic criteria which include symptoms, elevated pancreatic enzymes, and an abnormal pancreatic image.

bSubset of patients with acute pancreatitis who also had both elevated pancreatic enzymes and an abnormal pancreatic image.

cSubset of patients with acute pancreatitis who had elevated pancreatic enzymes, an abnormal pancreatic image, and symptoms.

Pancreatitis in the AWARD-11 Study

The AWARD-11 trial was a phase 3, randomized, double-blind, active-controlled, parallel-arm study that assessed the efficacy and safety of dulaglutide 3.0 mg and 4.5 mg compared with dulaglutide 1.5 mg in patients with inadequately controlled T2D on concomitant metformin therapy.5

6 patients were reported with adjudication-confirmed acute pancreatitis including

  • 1 patient, 0.2%, in the dulaglutide 1.5 mg group
  • 2 patients, 0.3%, in the dulaglutide 3.0 mg group, and
  • 3 patients, 0.5%, in the dulaglutide 4.5 mg  group.6

All cases were acute and were reported as mild in severity with no pancreatic complications.6

One patient who was assigned to dulaglutide 4.5 mg, with a confirmed case of acute pancreatitis, had a previously undisclosed history of pancreatitis and would have been excluded from enrollment had this been known at the time of screening.6


1Nauck MA, Frossard JL, Barkin JS, et al. Assessment of pancreas safety in the development program of once-weekly GLP-1 receptor agonist dulaglutide. Diabetes Care. 2017;40(5):647-654.

2Trulicity [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.

3Gerstein HC, Colhoun HM, Dagenais GR, et al; REWIND Trial Investigators. Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide. Diabetes Obes Metab. 2018;20(1):42-49.

4Gerstein HC, Colhoun HM, Dagenais GR, et al; REWIND Investigators. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121-130.

5Frias JP, Nevárez Ruiz L, Li YG, et al. Efficacy and safety of higher dulaglutide doses (3.0 mg and 4.5 mg) when added to metformin in patients with type 2 diabetes: a phase 3, randomized, double-blind, parallel arm study (AWARD-11). J Endocr Soc. 2020;4(suppl 1):A1036. Endocrine Society abstract OR26-08.

6Data on file, Eli Lilly and Company and/or one of its subsidiaries.

Date of Last Review: 05 October 2020

Contact Lilly

Call or Email us

If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at

Available Mon - Fri, 10am - 4pm, excluding Bank Holidays

Or you can

Chat with Us

Click to Chat is Offline

If you have a question, you can chat online with a Lilly Medical Information professional.

Submit a request